A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico-Reference-Cited by-同舟云学术

A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico

Published:2023-07-15 Issue:5 Volume:7 Page:841-849
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Garnica-Cuellar Juan Carlos^ORCID,Morales-Villegas Enrique^ORCID,López-Forero Carmen Alicia^ORCID,Monroy-Cruz Bárbara,Pariti Bhrugu,Deshwal Swati,Sekharan Manisha,Osorio-Hernández Mariana^ORCID,García-Appendini Ida Caterina^ORCID

Funder

Novo Nordisk Mexico

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-023-00421-2.pdf

Reference39 articles.

1. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM Int J Med. 2003;96:281–8. https://doi.org/10.1093/qjmed/hcg040.

2. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición 2018–19. Cuernavaca, Morelos, México; 2020. https://ensanut.insp.mx/encuestas/ensanut2018/doctos/informes/ensanut_2018_informe_final.pdf.

3. Dirección General de Epidemiología. Anuario de morbilidad 1984–2020. México; 2022. https://epidemiologia.salud.gob.mx/anuario/html/index.html.

4. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577–83. https://doi.org/10.1007/s001250050617.

5. The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study. The DCCT Research Group. Diabetes Care. 1987;10:1–19. https://doi.org/10.2337/diacare.10.1.1.